Lakefront Biotherapeutics LKFT
$33.31 −$0.08 (-0.24%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $33.31 0.00%
Open$33.61
Prev close$33.39
Day range$33.25 – $33.85
Volume162.5K
Market cap$2.18B
P/E (TTM)2.5
Dividend yield–
LKFT Stock News
Headlines matching Lakefront Biotherapeutics or the LKFT ticker, most recent first.
- RBC Capital Upgrades Lakefront Biotherapeutics(LKFT.US) to Buy Rating, Raises Target Price to $45 Positive
- Morgan Stanley Upgrades Lakefront Biotherapeutics(LKFT.US) to Hold Rating, Raises Target Price to $30 Positive
- Morgan Stanley Maintains Lakefront Biotherapeutics(LKFT.US) With Hold Rating, Maintains Target Price $30
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR)
- RBC Capital Initiates Lakefront Biotherapeutics(LKFT.US) With Hold Rating, Announces Target Price $28
- TD Cowen Initiates Lakefront Biotherapeutics(LKFT.US) With Buy Rating
- RBC Capital Maintains Lakefront Biotherapeutics(LKFT.US) With Buy Rating, Maintains Target Price $45
No comments yet — be the first to weigh in on LKFT.
Sign in to join the discussion.